1-20 of 80 Search Results for

Ocean

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal: Blood
Blood (2021) 138 (Supplement 1): 4777.
Published: 2021
... . 2021;39:757). In OCEAN (NCT03151811), a randomized, phase 3 study, melflufen + dex showed superior progression-free survival (PFS) vs pomalidomide + dex in RRMM (Oncopeptides. Press release. Jul 8, 2021). This subgroup analysis of OCEAN investigates the impact of melflufen + dex in pts with RI. Methods...
Journal Articles
Journal: Blood
Blood (2021) 138 (Supplement 1): 4779.
Published: 2021
... with RRMM show that melflufen is active in pts who have prior exposure to alkylator therapy, and safety signals were not impacted by prior alkylator exposure (Rodriguez-Otero, et al. ASCO . 2021; Poster 8048). Topline results from the phase 3 randomized OCEAN study demonstrated the primary endpoint was met...
Journal Articles
Journal: Blood
Blood (2021) 138 (Supplement 1): 4780.
Published: 2021
.... In the United States, melflufen + dex received accelerated approval in RRMM based on results from the phase 2 HORIZON study (Richardson et al. J Clin Oncol . 2021;39:757). In the phase 3, randomized, OCEAN study (NCT03151811), melflufen + dex significantly reduced the risk of disease progression vs pom + dex...
Journal Articles
Journal: Blood
Blood (2021) 138 (Supplement 1): 2732.
Published: 2021
... survival benefit (HR, 1.10 [95% CI, 0.85-1.44]) in the phase 3 randomized OCEAN study (NCT03151811; Oncopeptides. Press release. Jul 8, 2021). This abstract reports the first high-level safety and tolerability data from OCEAN. Methods: Pts with RRMM (2-4 prior lines of therapy [LoTs], including...
Journal Articles
Journal: Blood
Blood (2021) 138 (Supplement 1): 2741.
Published: 2021
... study (OP-106; NCT02963493; Richardson et al. J Clin Oncol. 2021;39:757), which led to its accelerated approval in the United States. In the phase 3 OCEAN study (OP-103; NCT03151811; Oncopeptides. Press release. July 8, 2021), a head-to-head comparison of melflufen + dex and pomalidomide (pom) + dex...
Journal Articles
Journal: Blood
Blood (2017) 130 (24): 2578–2579.
Published: 2017
... are isotonic. 2 , 3 Water in pools and rivers is hypotonic compared with sea water, but water from the Dead Sea is hypertonic. Swimming in the ocean or sea is relatively easier than swimming in a pool or river due to the buoyancy of seawater, which contains ∼3.5% salt. Floating, rather than swimming...
Journal Articles
Journal Articles
Clinical Trials & Observations Global Advances
Blood Adv (2021) 5 (5): 1403–1411.
Published: 2021
... from January 2019 and followed up through October 2020 at Ocean Road Cancer Institute. Information was obtained at the time of diagnosis and follow-up. Blood samples were collected in EDTA tubes to measure the BCR/ABL ratio on the Gene Xpert system for molecular response determination. The median age...
Includes: Supplemental data
News
Published: 2021
...The OCEAN study evaluating melphalan flufenamide and dexamethasone for the treatment of patients with multiple myeloma (MM) found an increased risk of death, according to a U.S. Food and Drug Administration (FDA) alert.   The FDA requires that Oncopeptides AB, the manufacturer...)
Journal Articles
Journal Articles
Journal Articles
Clinical Trials & Observations
Journal: Blood
Blood (2016) 127 (1): 5–6.
Published: 2016
... of the southeast Pacific Ocean and named it Easter Island. That Dutch landing party and subsequent visitors to these islands, known by the locals as Rapa Nui Island, have marveled at the sight of gigantic stone figures (up to 30-feet high) of porous red rock known as moai, standing in silent rows along the shore...
Journal Articles
Journal: Blood
Blood (2021) 138 (Supplement 1): 4003.
Published: 2021
... in daily practice. There has been significant advancement in treating multiple myeloma (MM) over the past two decades bringing multiple new mechanisms of action to the bedside. We selected ten recent RCTs: ASPIRE, TOURMALNE-MM01, ELOQUENT-2, ENDEAVOR, POLLUX and CASTOR, OCEAN, ICARIA, APOLLO and ELOQUENT-3...
Journal Articles
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
Published: 2020
.... Alkylating agents In a phase I/II trial (NCT01897714, N=45), melphalan-flufenamide (melflufan) + Dex yielded an ORR of 31%, it was well tolerated with 49% CB. Phase III OCEAN trial (NCT03151811, N=450) is currently ongoing to compare melflufen + Dex vs. pomalidomide (Pom) + Dex. Apoptotic agents A phase 3...
Journal Articles
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
Published: 2020
... in some regions close to the Pacific and Atlantic Oceans, with carrier frequencies from 0.5 to 12.8%, therefore Sickle Cell Disease patients are often seen in those regions. It is well known that increased levels of Fetal Hemoglobin (HbF) ameliorates the clinical complications of sickle cell disease...
Journal Articles
Journal Articles
Journal: Blood
Blood (2019) 134 (Supplement_1): 1839.
Published: 2019
... of additional follow-up of patients with late-stage, heavily pretreated RRMM who have relapsed on conventional therapy including bortezomib and lenalidomide. Further trials are ongoing to evaluate efficacy and safety of melflufen, including the phase 3 study OCEAN (OP-103; NCT03151811) of melflufen plus...
Journal Articles
Journal: Blood
Blood (2017) 130 (Supplement 1): 1841.
Published: 2017
...), and are refractory to pomalidomide and/or daratumumab. Phase 1/2 of melflufen in combination with dexamethasone has been completed (O-12-M1), while phase 2 (Horizon) and phase 3 (Ocean) studies are ongoing. Methods: Melflufen 40 mg is given i.v. on Day 1 of each 28-day cycle, with dexamethasone 40 mg weekly, in RRMM...
Journal Articles
Journal: Blood
Blood (2017) 130 (Supplement 1): 3150.
Published: 2017
..., with limited treatment options, are both encouraging at 5.1 months and 20.7 months, respectively. The long median OS of 27.2 months in patients that only achieved SD as best response will be further studied in the ongoing studies OCEAN (phase 3) and HORIZON (phase 2). Treatment-related hematologic toxicity...
Journal Articles
Journal: Blood
Blood (2016) 128 (22): 4994.
Published: 2016
... history of VTE. The purpose of this study was to review the practices in thrombophilia testing at Jersey Shore University Medical Center (JSUMC) and Ocean Medical Center (OMC) with respect to these recent recommendations. Methods: A retrospective review at JSUMC and OMC was performed of all adult...